We combine our CJC 1295 & Ipamorelin which provides as synergistic effect, which has five times the benefits of using them alone. The combination allows a maximized release of GH because they each have a different mechanism of action, working on different receptors. Ipamorelin is a selective GH-Secretagogue and ghrelin receptor agonist.
The potency of ghrelin stimulation can be compared to GHRP6 with less appetite stimulation properties. However, unlike other GH-Secretagogues this pentapeptide doesn’t release the same volumes of cortisol, acetylcholine, prolactin and aldosterone. For this reason, Ipamorelin has been considered the first selective GH which promotes secretion.
CJC 1295 stimulates growth hormone secretion and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to fat loss, and increased protein synthesis, in turn promoting growth. CJC 1295 is a tetrasubstituted 29-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog.
CJC 1295 performs better than the older and outdated GHRH, Sermorelin. Sermorelin’s efficacy decreases with time and the body produces antibodies to Sermorelin, bioconjugate with serum albumin, thus increasing its half-life and potential therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation, thus increasing the half-life.
Consequently CJC 129 without DAC is designed to provide a GHRH-like stimulation around the clock with increased amplitude and longer stimulation, (28 minutes instead of 8-12 of sermorelin), maintaining the natural pulsatile stimulation of the pituitary without decreasing secretion as observed in CJC with DAC. CJC-1295 CJC-1295 IPAMORELIN COA.
Summary of published preclinical and clinical literature, provided for research context only. Not a claim of efficacy and not medical advice.
